{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T16:32:53Z","timestamp":1790181173068,"version":"4.1.0"},"reference-count":22,"publisher":"Harborside Press, LLC","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,8]]},"abstract":"<jats:p>The estimated 5-year survival rate for patients with stage IV uterine leiomyosarcoma is 29%, with a median survival of &lt;1 year. This report describes a patient with stage IVB leiomyosarcoma who experienced stable disease for 15 months on pembrolizumab. A woman aged 62 years, gravida 2 para 2, with postmenopausal bleeding and a necrotic uterine fibroid underwent a dilation and curettage and was diagnosed with uterine leiomyosarcoma. CT imaging showed pulmonary and bony metastasis. She underwent surgical staging with biopsy-proved stage IVB disease. A mixed partial response was noted using first- and second-line chemotherapy. Molecular tumor profiling confirmed PD-L1 expression. The patient was started on pembrolizumab, and at the time of writing she is status post 23 cycles with stable disease. Pembrolizumab was well tolerated and aided prolonged disease stabilization.<\/jats:p>","DOI":"10.6004\/jnccn.2020.7562","type":"journal-article","created":{"date-parts":[[2020,8,5]],"date-time":"2020-08-05T19:25:28Z","timestamp":1596655528000},"page":"1012-1014","source":"Crossref","is-referenced-by-count":6,"title":["Stabilization of Metastatic Uterine Leiomyosarcoma Using Pembrolizumab"],"prefix":"10.6004","volume":"18","author":[{"given":"Katherine","family":"Cotangco","sequence":"first","affiliation":[{"name":"1Department of Obstetrics and Gynecology, University of Illinois;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"Meram","sequence":"additional","affiliation":[{"name":"2Department of Obstetrics and Gynecology, Amita Health Hospital; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Patrick","family":"Lowe","sequence":"additional","affiliation":[{"name":"3Gynecologic Cancer Institute, Chicago, Illinois."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"4047","reference":[{"key":"ref161","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.ygyno.2008.03.010","article-title":"Fixed-dose rate gemcitabine plus docetaxel as first-line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group phase II trial","volume":"109","author":"Hensley","year":"2008","journal-title":"Gynecol Oncol"},{"key":"ref151","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.ygyno.2008.02.024","article-title":"Fixed-dose rate gemcitabine plus docetaxel as second-line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group phase II study","volume":"109","author":"Hensley","year":"2008","journal-title":"Gynecol Oncol"},{"key":"ref141","first-page":"1","article-title":"YasharCM BeanS Guidelines in Uterine Version Accessed To view the most recent version visitNCCN org","volume":"30","author":"RustumNR","year":"2020","journal-title":"Clinical Practice Oncology"},{"key":"ref201","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.immuni.2017.02.001","article-title":"Loss of PTEN is associated with resistance to anti-PD-1 checkpoint blockade therapy in metastatic uterine leiomyosarcoma","volume":"46","author":"George","year":"2017","journal-title":"Immunity"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.ygyno.2008.02.024","article-title":"Fixed-dose rate gemcitabine plus docetaxel as second-line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group phase II study","volume":"109","author":"Hensley","year":"2008","journal-title":"Gynecol Oncol"},{"key":"ref71","doi-asserted-by":"crossref","first-page":"43","DOI":"10.4143\/crt.2012.44.1.43","article-title":"Weekly gemcitabine and docetaxel in refractory soft tissue sarcoma: a retrospective analysis","volume":"44","author":"Lee","year":"2012","journal-title":"Cancer Res Treat"},{"key":"ref191","article-title":"approval Accessed Available at https www drugs com history keytruda html","volume":"25","author":"StewartJ","year":"2020","journal-title":"history"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1016\/j.ygyno.2018.09.010","article-title":"Uterine leiomyosarcoma: a review of the literature and update on management options","volume":"151","author":"Roberts","year":"2018","journal-title":"Gynecol Oncol"},{"key":"ref61","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1097\/CCO.0000000000000094","article-title":"Management of advanced uterine leiomyosarcoma","volume":"26","author":"Hyman","year":"2014","journal-title":"Curr Opin Oncol"},{"key":"ref01","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1016\/S1470-2045(17)30624-1","article-title":"Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial","volume":"18","author":"Tawbi","year":"2017","journal-title":"Lancet Oncol"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"S61","DOI":"10.1097\/IGC.0000000000000261","article-title":"Gynecologic Cancer InterGroup (GCIG) consensus review: uterine and ovarian leiomyosarcomas","volume":"24","author":"Hensley","year":"2014","journal-title":"Int J Gynecol Cancer"},{"key":"ref101","doi-asserted-by":"crossref","first-page":"2535","DOI":"10.1200\/JCO.2017.72.5952","article-title":"Safety and antitumor activity of pembrolizumab in advanced programmed death ligand 1-positive endometrial cancer: results from the KEYNOTE-028 study","volume":"35","author":"Ott","year":"2017","journal-title":"J Clin Oncol"},{"key":"ref31","first-page":"1","article-title":"YasharCM BeanS Guidelines in Uterine Version Accessed To view the most recent version visitNCCN org","volume":"30","author":"RustumNR","year":"2020","journal-title":"Clinical Practice Oncology"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.ygyno.2008.03.010","article-title":"Fixed-dose rate gemcitabine plus docetaxel as first-line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group phase II trial","volume":"109","author":"Hensley","year":"2008","journal-title":"Gynecol Oncol"},{"key":"ref111","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1016\/S1470-2045(17)30624-1","article-title":"Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial","volume":"18","author":"Tawbi","year":"2017","journal-title":"Lancet Oncol"},{"key":"ref211","doi-asserted-by":"crossref","first-page":"2535","DOI":"10.1200\/JCO.2017.72.5952","article-title":"Safety and antitumor activity of pembrolizumab in advanced programmed death ligand 1-positive endometrial cancer: results from the KEYNOTE-028 study","volume":"35","author":"Ott","year":"2017","journal-title":"J Clin Oncol"},{"key":"ref181","doi-asserted-by":"crossref","first-page":"43","DOI":"10.4143\/crt.2012.44.1.43","article-title":"Weekly gemcitabine and docetaxel in refractory soft tissue sarcoma: a retrospective analysis","volume":"44","author":"Lee","year":"2012","journal-title":"Cancer Res Treat"},{"key":"ref81","article-title":"approval Accessed Available at https www drugs com history keytruda html","volume":"25","author":"StewartJ","year":"2020","journal-title":"history"},{"key":"ref121","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1016\/j.ygyno.2018.09.010","article-title":"Uterine leiomyosarcoma: a review of the literature and update on management options","volume":"151","author":"Roberts","year":"2018","journal-title":"Gynecol Oncol"},{"key":"ref91","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.immuni.2017.02.001","article-title":"Loss of PTEN is associated with resistance to anti-PD-1 checkpoint blockade therapy in metastatic uterine leiomyosarcoma","volume":"46","author":"George","year":"2017","journal-title":"Immunity"},{"key":"ref131","doi-asserted-by":"crossref","first-page":"S61","DOI":"10.1097\/IGC.0000000000000261","article-title":"Gynecologic Cancer InterGroup (GCIG) consensus review: uterine and ovarian leiomyosarcomas","volume":"24","author":"Hensley","year":"2014","journal-title":"Int J Gynecol Cancer"},{"key":"ref171","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1097\/CCO.0000000000000094","article-title":"Management of advanced uterine leiomyosarcoma","volume":"26","author":"Hyman","year":"2014","journal-title":"Curr Opin Oncol"}],"container-title":["Journal of the National Comprehensive Cancer Network"],"original-title":[],"link":[{"URL":"https:\/\/jnccn.org\/view\/journals\/jnccn\/18\/8\/article-p1012.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/jnccn.org\/downloadpdf\/journals\/jnccn\/18\/8\/article-p1012.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,23]],"date-time":"2020-10-23T18:36:03Z","timestamp":1603478163000},"score":1,"resource":{"primary":{"URL":"https:\/\/jnccn.org\/view\/journals\/jnccn\/18\/8\/article-p1012.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8]]},"references-count":22,"journal-issue":{"issue":"8"},"URL":"https:\/\/doi.org\/10.6004\/jnccn.2020.7562","relation":{},"ISSN":["1540-1405","1540-1413"],"issn-type":[{"value":"1540-1405","type":"print"},{"value":"1540-1413","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8]]}}}